[go: up one dir, main page]

TW200640876A - 1H-imidazole derivatives as cannabinoid CB2 receptor modulators - Google Patents

1H-imidazole derivatives as cannabinoid CB2 receptor modulators

Info

Publication number
TW200640876A
TW200640876A TW095104715A TW95104715A TW200640876A TW 200640876 A TW200640876 A TW 200640876A TW 095104715 A TW095104715 A TW 095104715A TW 95104715 A TW95104715 A TW 95104715A TW 200640876 A TW200640876 A TW 200640876A
Authority
TW
Taiwan
Prior art keywords
imidazole derivatives
cannabinoid
receptor modulators
receptors
compounds
Prior art date
Application number
TW095104715A
Other languages
Chinese (zh)
Inventor
Josephus H M Lange
Van Herman H Stuivenberg
Van Bernard J Vliet
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of TW200640876A publication Critical patent/TW200640876A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a group of 1H-imidazole derivatives which are modulators of cannabinoid CB2 receptors, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of said imidazole derivatives, to methods for the preparation of these intermediates, to pharmaceutical compositions containing one or more of these 1H-imidazole derivatives as active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which cannabinoid CB2 receptors are involved. The compounds have the general formula (I), wherein R1-R4 have the meanings given in the specification.
TW095104715A 2005-02-16 2006-02-13 1H-imidazole derivatives as cannabinoid CB2 receptor modulators TW200640876A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05101171 2005-02-16

Publications (1)

Publication Number Publication Date
TW200640876A true TW200640876A (en) 2006-12-01

Family

ID=34938748

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095104715A TW200640876A (en) 2005-02-16 2006-02-13 1H-imidazole derivatives as cannabinoid CB2 receptor modulators

Country Status (5)

Country Link
KR (1) KR20070107130A (en)
CN (1) CN101107233A (en)
AR (1) AR052666A1 (en)
TW (1) TW200640876A (en)
UA (1) UA92736C2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990564A1 (en) * 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic heterocyclic amide derivative
CA2990583A1 (en) * 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
CN107663159A (en) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 Polycyclic compound, its pharmaceutical composition and application

Also Published As

Publication number Publication date
UA92736C2 (en) 2010-12-10
AR052666A1 (en) 2007-03-28
CN101107233A (en) 2008-01-16
KR20070107130A (en) 2007-11-06

Similar Documents

Publication Publication Date Title
NO20074710L (en) 1H-Imidazole derivatives as cannabinoid CB2 receptor modulators
WO2009010871A3 (en) Pyrazole derivatives as antagonists of adenosine a3 receptor
BRPI0507005A (en) compounds, pharmaceutical compositions, use of a compound, and method of preparing a pharmaceutical composition
WO2009010455A3 (en) Pyrazole derivatives as modulators of metabotropic glutamate receptors
EA200870079A1 (en) SUBSTITUTED IMIDAZOLES AND THEIR APPLICATION AS PESTICIDES
MX2011006132A (en) Fused imidazole carboxamides as trpv3 modulators.
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
MA34094B1 (en) 3- (HETEROARYLAMINO) -1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE PROSTAGLANDIN D2 RECEPTOR
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
MX2007002393A (en) Substituted indole compounds and their use as 5-ht6 receptor modulators.
WO2009116074A3 (en) Substituted benzimidazoles as cannabinoid modulator
MX2011006821A (en) Fused imidazole derivatives as trpv3 antagonist.
MX2010005704A (en) Chromane derivatives as trpv3 modulators.
ATE411296T1 (en) IMIDAZOLINE DERIVATIVES WITH CB1 ANTAGONISTIC EFFECT
EA200870606A1 (en) SERO-CONTAINING DERIVATIVES OF PYRAZOL AS AN ELECTORAL ANTAGONISTS OF CANA CANNABINOID RECEPTOR
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
UA100862C2 (en) Hexatomic aromatic compounds, preparation and use thereof
NO20062249L (en) 1H-imidazole derivatives as cannabionide receptor modulators
WO2009034432A8 (en) Novel compounds active as muscarinic receptor antagonists
UA104861C2 (en) Chromane derivatives as trpv3 modulators
TW200640876A (en) 1H-imidazole derivatives as cannabinoid CB2 receptor modulators
WO2007042544A3 (en) Imidazole derivatives and their use for modulating the gabaa receptor complex
WO2006025069A3 (en) Tricyclic pyrazole derivatives as cannabinoid receptor modulators
EA201071227A1 (en) (5R) -1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOL-3-CARBOXAMIDINE DERIVATIVES, possessing CB1-ANTAGONISTIC ACTIVITY
EA201190003A1 (en) CHROMENON DERIVATIVES AS TRPV3 ANTAGONISTS